First Trust NYSE Arca Biotechnology Index Fund FBT AMEX · Financials · United States
$270.64 -0.14% -$0.39
Summary
First Trust NYSE Arca Biotechnology Index Fund is an ETF - a fund traded on an exchange like a stock - run by First Trust. Positions inside: 31. The ten largest make up 40% of the fund.
- Yearly costs
- 0.55%
- Fund size
- $3.08B
- Positions
- 31
- Running since
- 2006
What speaks for it
- A large fund with $3.08B under management.
- Easy to buy and sell: about $20.0M changes hands a day.
- Average yearly growth over the last ten years: 11%.
- It has been running since 2006.
What to watch
- 100% of the fund is in one sector (Healthcare).
- 95% of the fund is in one country (United States).
- Costs of 0.55% a year are above the middle of comparable funds (0.45%).
- In the last five years its price once dropped by 33% from its high.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- +2.8%
- 3 months
- +6.1%
- This year
- +31%
- 1 year
- +36%
- 3 years
- +96%
- 5 years
- +69%
- 10 years
- +173%
- Avg. market cap
- $42.1B
- P/E
- 28.0x
- Forward P/E
- 22.8x
- P/S
- 5.7x
- P/B
- 4.6x
- P/FCF
- 28.2x
- EV/EBITDA
- 25.3x
- Dividend yield
- 0.19%
- ROIC
- 0.7%
- ROE
- 17.4%
- Gross margin
- 79.4%
- Operating margin
- 12.7%
- Net margin
- 7.9%
- Payout ratio
- 5.3%
- Net debt/EBITDA
- 2.2x
- Beta
- 0.76
Weighted average of the 30 largest companies, which make up 100% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Moderately concentrated- 1 GMGenmab A/S GMAB 4.5%
- 2 ADADMA Biologics ADMA 4.3%
- 3 RERegeneron Pharmaceuticals REGN 4.2%
- 4 NBNeurocrine Biosciences NBIX 3.8%
- 5 ONBeOne Medicines AG ONC 3.8%
- 6 TGTG Therapeutics TGTX 3.8%
- 7 ARArgenx ARGX 3.8%
- 8 ALAlkermes ALKS 3.8%
- 9 EXExelixis EXEL 3.8%
- 10 BIBiogen BIIB 3.7%
Positions in the fund: 31. The ten largest make up 40% of it.
Composition as of Nov 14, 2026.
Where is it spread?
One sector dominatesBy sector
- Healthcare 100%
By country
- United States 95%
- Denmark 4.6%
By company size
- Mega cap 7.3%
- Large cap 61%
- Mid cap 30%
- Small cap 1.8%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest sector: Healthcare (100%). Largest country: United States (95%). Largest size group: Large cap (61%).
What does it cost me?
Expensive- A year from $10,000
- $55.00
- Over 20 years
- $2,646
From every $10,000 invested the fund takes $55.00 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about $2,646.
How has it done?
Growing over the long run- A year on average, 10 years
- +11%
- Deepest drop
- -33%
- Yearly volatility
- 22%
Average yearly growth over the last ten years: 11%. Deepest drop in these years: 33% below the earlier high.
Does it pay dividends?
Yes, it pays out- Last payment
- $1.17
The last payment was $1.17 on Dec 13, 2024.
Is it easy to buy and sell?
Very easy- Traded a day
- $20.0M
- Shares a day
- 74K
On an average day about $20.0M of the fund changes hands.
How expensive are the companies inside?
Rather expensive- P/E of the companies inside
- 28.0
- Average Bulios Score
- 57 out of 100
Weight by Bulios Fair Price
- Undervalued 40%
- Fairly valued 17%
- Overvalued 43%
On average the companies inside trade for 28.0 times their yearly profit. By Fair Price, 43% of the rated weight comes out as overvalued.
Counted from its largest companies (30), which make up 100% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
PB PBE Invesco Biotechnology & Genome ETF | United States | 0.59% | $298.4M | +26% | Pays out | 48% |
IB IBB iShares Biotechnology ETF | United States | 0.44% | $11.0B | +29% | Pays out | 44% |
BB BBH VanEck Biotech ETF | United States | 0.35% | $534.9M | +34% | Pays out | 41% |
FT FTXH First Trust Nasdaq Pharmaceuticals ETF | United States | 0.60% | $1.20B | +41% | Pays out | 35% |
20 203780.KS MiraeAsset TIGER NASDAQ BIO ETF | South Korea | 0.30% | $79.3M | +19% | Reinvests | 34% |
SB SBIO.MI Invesco NASDAQ Biotech UCITS ETF | Ireland | 0.40% | $651.6M | +36% | Reinvests | 33% |